MSIF’s 2023 application to the WHO Essential Medicines List

The Lancet Neurology, 2023;22(3):189. doi:10.1016/S1474-4422(23)00041-8

Application to WHO EML, 2022

ECTRIMS Podcast, Episode 12

Yamout BI, Viswanathan S, Laurson-Doube J and Sokhi D. Multiple Sclerosis Journal.

MSIF’s 2019 application to the WHO Essential Medicines List

The Lancet Neurology, 2019;18(12):1067. doi:10.1016/S1474-4422(19)30390-4

Laurson-Doube J, et al. The Lancet Neurology, 2020;19(3):207-208. doi:10.1016/S1474-4422(19)30486-7

McDonell J, Costello K, Laurson-Doube J, et al. Multiple Sclerosis Journal. 2020;26(2):153-158. doi:10.1177/1352458519898340

Off-label MS DMTs

Laurson-Doube J, Rijke N, Helme A, et al. Multiple Sclerosis Journal. 2021;27(9):1403-1410. doi:10.1177/13524585211030207

Pandit L. Multiple Sclerosis Journal. 2021; 27(9) doi:10.1177/1352458521102

Piggott T, Nonino F, Baldin E, et al. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2021;7(4). doi:10.1177/20552173211051855

Barriers to accessing treatment

Zeineddine M, Al-Hajje A, Salameh P, et al. MSARD. doi:10.1016/j.msard.2023.104959

Barriers to diagnosis

Solomon A, Marrie RA, Viswanathan S et al. Neurology.

Kock-Henriksen N. Neurology. doi:

The WHO intersectoral global action plan for epilepsy and other neurological disorders

World Health Organization

Owolabi M, Leonardi M, Bassetti C et al. Nature Reviews Neurology. 2023;19:371–383. doi:10.1038/s41582-023-00808-z